Financhill
Sell
37

EYPT Quote, Financials, Valuation and Earnings

Last price:
$6.24
Seasonality move :
17.06%
Day range:
$6.33 - $6.69
52-week range:
$5.54 - $23.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.63x
P/B ratio:
1.35x
Volume:
580K
Avg. volume:
928.8K
1-year change:
-69.13%
Market cap:
$455.7M
Revenue:
$43.3M
EPS (TTM):
-$2.31

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EYPT
EyePoint Pharmaceuticals
$11M -$0.48 -24.38% -22.59% $33.00
EDIT
Editas Medicine
$37.2M -$0.33 -23.05% -22.53% $3.75
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
OCGN
Ocugen
$300K -$0.05 -100% -- $6.75
OCUL
Ocular Therapeutix
$16.9M -$0.22 16.58% -42.86% $17.50
REGN
Regeneron Pharmaceuticals
$3.7B $11.19 9.12% 53% $923.05
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EYPT
EyePoint Pharmaceuticals
$6.63 $33.00 $455.7M -- $0.00 0% 8.63x
EDIT
Editas Medicine
$1.41 $3.75 $117M -- $0.00 0% 3.59x
NBY
NovaBay Pharmaceuticals
$0.64 $0.85 $3.1M -- $0.00 0% 0.07x
OCGN
Ocugen
$0.57 $6.75 $167.2M -- $0.00 0% 38.26x
OCUL
Ocular Therapeutix
$7.94 $17.50 $1.3B -- $0.00 0% 19.72x
REGN
Regeneron Pharmaceuticals
$678.42 $923.05 $74.2B 17.72x $0.88 0.13% 5.50x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EYPT
EyePoint Pharmaceuticals
-- -2.597 -- 7.57x
EDIT
Editas Medicine
-- 0.335 -- 3.71x
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
OCGN
Ocugen
49.18% 4.395 12.22% 2.71x
OCUL
Ocular Therapeutix
17.85% 3.384 5.09% 10.26x
REGN
Regeneron Pharmaceuticals
6.33% 0.941 2.54% 3.86x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EYPT
EyePoint Pharmaceuticals
$10.8M -$45.2M -50.34% -50.34% -356.36% -$36.2M
EDIT
Editas Medicine
-- -$34.4M -100% -100% -112.28% -$51.3M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
OCGN
Ocugen
-- -$13.8M -136.46% -171.04% -1811.52% -$10.4M
OCUL
Ocular Therapeutix
$15.9M -$50.6M -51.22% -62.66% -265.09% -$39.6M
REGN
Regeneron Pharmaceuticals
$3.2B $1B 14.73% 15.78% 25.56% $995.8M

EyePoint Pharmaceuticals vs. Competitors

  • Which has Higher Returns EYPT or EDIT?

    Editas Medicine has a net margin of -357.26% compared to EyePoint Pharmaceuticals's net margin of -148.33%. EyePoint Pharmaceuticals's return on equity of -50.34% beat Editas Medicine's return on equity of -100%.

    Company Gross Margin Earnings Per Share Invested Capital
    EYPT
    EyePoint Pharmaceuticals
    92.96% -$0.64 $336.5M
    EDIT
    Editas Medicine
    -- -$0.55 $134.3M
  • What do Analysts Say About EYPT or EDIT?

    EyePoint Pharmaceuticals has a consensus price target of $33.00, signalling upside risk potential of 397.74%. On the other hand Editas Medicine has an analysts' consensus of $3.75 which suggests that it could grow by 165.96%. Given that EyePoint Pharmaceuticals has higher upside potential than Editas Medicine, analysts believe EyePoint Pharmaceuticals is more attractive than Editas Medicine.

    Company Buy Ratings Hold Ratings Sell Ratings
    EYPT
    EyePoint Pharmaceuticals
    9 0 0
    EDIT
    Editas Medicine
    4 9 0
  • Is EYPT or EDIT More Risky?

    EyePoint Pharmaceuticals has a beta of 1.409, which suggesting that the stock is 40.932% more volatile than S&P 500. In comparison Editas Medicine has a beta of 1.876, suggesting its more volatile than the S&P 500 by 87.581%.

  • Which is a Better Dividend Stock EYPT or EDIT?

    EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EYPT or EDIT?

    EyePoint Pharmaceuticals quarterly revenues are $11.6M, which are smaller than Editas Medicine quarterly revenues of $30.6M. EyePoint Pharmaceuticals's net income of -$41.4M is higher than Editas Medicine's net income of -$45.4M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 8.63x versus 3.59x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EYPT
    EyePoint Pharmaceuticals
    8.63x -- $11.6M -$41.4M
    EDIT
    Editas Medicine
    3.59x -- $30.6M -$45.4M
  • Which has Higher Returns EYPT or NBY?

    NovaBay Pharmaceuticals has a net margin of -357.26% compared to EyePoint Pharmaceuticals's net margin of -49.65%. EyePoint Pharmaceuticals's return on equity of -50.34% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    EYPT
    EyePoint Pharmaceuticals
    92.96% -$0.64 $336.5M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About EYPT or NBY?

    EyePoint Pharmaceuticals has a consensus price target of $33.00, signalling upside risk potential of 397.74%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that EyePoint Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe EyePoint Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    EYPT
    EyePoint Pharmaceuticals
    9 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is EYPT or NBY More Risky?

    EyePoint Pharmaceuticals has a beta of 1.409, which suggesting that the stock is 40.932% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock EYPT or NBY?

    EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EYPT or NBY?

    EyePoint Pharmaceuticals quarterly revenues are $11.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. EyePoint Pharmaceuticals's net income of -$41.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 8.63x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EYPT
    EyePoint Pharmaceuticals
    8.63x -- $11.6M -$41.4M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns EYPT or OCGN?

    Ocugen has a net margin of -357.26% compared to EyePoint Pharmaceuticals's net margin of -1816.75%. EyePoint Pharmaceuticals's return on equity of -50.34% beat Ocugen's return on equity of -171.04%.

    Company Gross Margin Earnings Per Share Invested Capital
    EYPT
    EyePoint Pharmaceuticals
    92.96% -$0.64 $336.5M
    OCGN
    Ocugen
    -- -$0.05 $58.3M
  • What do Analysts Say About EYPT or OCGN?

    EyePoint Pharmaceuticals has a consensus price target of $33.00, signalling upside risk potential of 397.74%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 1078.83%. Given that Ocugen has higher upside potential than EyePoint Pharmaceuticals, analysts believe Ocugen is more attractive than EyePoint Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    EYPT
    EyePoint Pharmaceuticals
    9 0 0
    OCGN
    Ocugen
    2 0 0
  • Is EYPT or OCGN More Risky?

    EyePoint Pharmaceuticals has a beta of 1.409, which suggesting that the stock is 40.932% more volatile than S&P 500. In comparison Ocugen has a beta of 3.883, suggesting its more volatile than the S&P 500 by 288.285%.

  • Which is a Better Dividend Stock EYPT or OCGN?

    EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EYPT or OCGN?

    EyePoint Pharmaceuticals quarterly revenues are $11.6M, which are larger than Ocugen quarterly revenues of $764K. EyePoint Pharmaceuticals's net income of -$41.4M is lower than Ocugen's net income of -$13.9M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 8.63x versus 38.26x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EYPT
    EyePoint Pharmaceuticals
    8.63x -- $11.6M -$41.4M
    OCGN
    Ocugen
    38.26x -- $764K -$13.9M
  • Which has Higher Returns EYPT or OCUL?

    Ocular Therapeutix has a net margin of -357.26% compared to EyePoint Pharmaceuticals's net margin of -283.27%. EyePoint Pharmaceuticals's return on equity of -50.34% beat Ocular Therapeutix's return on equity of -62.66%.

    Company Gross Margin Earnings Per Share Invested Capital
    EYPT
    EyePoint Pharmaceuticals
    92.96% -$0.64 $336.5M
    OCUL
    Ocular Therapeutix
    92.8% -$0.29 $383.8M
  • What do Analysts Say About EYPT or OCUL?

    EyePoint Pharmaceuticals has a consensus price target of $33.00, signalling upside risk potential of 397.74%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 120.4%. Given that EyePoint Pharmaceuticals has higher upside potential than Ocular Therapeutix, analysts believe EyePoint Pharmaceuticals is more attractive than Ocular Therapeutix.

    Company Buy Ratings Hold Ratings Sell Ratings
    EYPT
    EyePoint Pharmaceuticals
    9 0 0
    OCUL
    Ocular Therapeutix
    5 0 0
  • Is EYPT or OCUL More Risky?

    EyePoint Pharmaceuticals has a beta of 1.409, which suggesting that the stock is 40.932% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.337, suggesting its more volatile than the S&P 500 by 33.685%.

  • Which is a Better Dividend Stock EYPT or OCUL?

    EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EYPT or OCUL?

    EyePoint Pharmaceuticals quarterly revenues are $11.6M, which are smaller than Ocular Therapeutix quarterly revenues of $17.1M. EyePoint Pharmaceuticals's net income of -$41.4M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 8.63x versus 19.72x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EYPT
    EyePoint Pharmaceuticals
    8.63x -- $11.6M -$41.4M
    OCUL
    Ocular Therapeutix
    19.72x -- $17.1M -$48.4M
  • Which has Higher Returns EYPT or REGN?

    Regeneron Pharmaceuticals has a net margin of -357.26% compared to EyePoint Pharmaceuticals's net margin of 24.22%. EyePoint Pharmaceuticals's return on equity of -50.34% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    EYPT
    EyePoint Pharmaceuticals
    92.96% -$0.64 $336.5M
    REGN
    Regeneron Pharmaceuticals
    85.08% $8.06 $31.3B
  • What do Analysts Say About EYPT or REGN?

    EyePoint Pharmaceuticals has a consensus price target of $33.00, signalling upside risk potential of 397.74%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 36.06%. Given that EyePoint Pharmaceuticals has higher upside potential than Regeneron Pharmaceuticals, analysts believe EyePoint Pharmaceuticals is more attractive than Regeneron Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    EYPT
    EyePoint Pharmaceuticals
    9 0 0
    REGN
    Regeneron Pharmaceuticals
    12 6 0
  • Is EYPT or REGN More Risky?

    EyePoint Pharmaceuticals has a beta of 1.409, which suggesting that the stock is 40.932% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

  • Which is a Better Dividend Stock EYPT or REGN?

    EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EYPT or REGN?

    EyePoint Pharmaceuticals quarterly revenues are $11.6M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. EyePoint Pharmaceuticals's net income of -$41.4M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 8.63x versus 5.50x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EYPT
    EyePoint Pharmaceuticals
    8.63x -- $11.6M -$41.4M
    REGN
    Regeneron Pharmaceuticals
    5.50x 17.72x $3.8B $917.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock